The Impact of Nerve Involvement on the Prognosis of Gastric Cancer Patients with Curative Gastrectomy: An International Multicenter Analysis

Kun Yang,1,2 Yu-Qing Dan,3 Yoon Young Choi,4 Zong-Guang Zhou,1 Woo Jin Hyung,4 Jian-Kun Hu,1,2 and Sung Hoon Noh5

1Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, China
2Laboratory of Gastric Cancer, State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital, Sichuan University, China
3West China School of Medicine, Sichuan University, China
4Department of Surgery, Severance Hospital, Yonsei University Health System, Yonsei University College of Medicine, Seoul, Republic of Korea
5Department of Surgery, Gangnam Severance Hospital, Yonsei University Health System, Yonsei University College of Medicine, Seoul, Republic of Korea

Correspondence should be addressed to Jian-Kun Hu; mdtwch@126.com and Sung Hoon Noh; sunghoonn@yuhs.ac

Received 20 September 2020; Revised 31 January 2021; Accepted 19 March 2021; Published 28 March 2021

Academic Editor: Jian-Guo Zhou

Copyright © 2021 Kun Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Several studies have been conducted to investigate the association between the presence of perineural invasion (PNI) and overall survival (OS) of gastric cancer (GC) patients who underwent curative resection, but no consensus has been reached. This study is aimed at determining the prognostic significance of PNI in gastric cancer. Study Design. The data of 2969 patients with gastric cancer and who had undergone curative gastrectomy from 2006 to 2010 in two high-volume hospitals of China and Korea were retrospectively analyzed. PNI positivity was identified when carcinoma cells were found to infiltrate into the perineurium or neural fascicles. The relationships between PNI and other clinicopathological factors were evaluated, and survival analyses were performed. Results. The presence of PNI was detected in 1055 of the 2969 patients (35.5%). Nationality, age, tumor location, size of tumor, differentiation of the tumor, pT stage, pN stage, lymphatic invasion, and vascular invasion had been associated with PNI positivity. The mean survival time of patients with and without PNI was 62.5 months and 87.3 months, respectively ($P < 0.001$). However, the presence of PNI was not an independent prognostic factor for gastric cancer, except for patients in stage III ($P = 0.037$, hazard ratio: 1.21, 95% confidence interval: 1.01-1.44). Conclusion. PNI occurs frequently in patients with gastric cancer, and the incidence of PNI increases with the staging of the tumor. The presence of PNI can provide additional information in predicting the survival outcome for those with stage III tumors.

1. Introduction

Gastric cancer (GC) has been a great threat to public health. Although the incidence of GC has been gradually decreasing during the past few decades, it is still the fifth most common cancer and the third most lethal cancer worldwide [1]. There were more than 900,000 new cases diagnosed annually and more than 700,000 deaths caused by GC in a year, and the prognosis was not promising with the cumulative 5-year survival in most countries remaining in the narrow range of 25-30% in recent years—except for Japan and Korea [2]. Depth of invasion, lymph node metastasis, and distant metastasis were well acknowledged to be the most important prognostic risk factors. Despite the TNM staging system which has greatly helped the doctors to assess patients’ prognosis and choose the stage-specific therapeutic strategy, the survival rates of patients with the same stage might have great differences, which means that other prognostic factors could
impact the overall survival of GC patients besides the TNM stage [3, 4]. Moreover, some studies also reported similar survival curves of different TNM stages [5, 6]. Therefore, discovering potential new biological or pathological indicators in GC to provide a more precise prediction for patients’ prognosis along with the existing prognostic factors would be necessary.

Perineural invasion (PNI) refers to the process by which cancer cells spread to the space surrounding a nerve. It is considered to be a prominent predictor for a more aggressive tumor phenotype and indicated poor prognosis in many carcinomas like prostatic cancer [7], bladder cancer [8, 9], and pancreatic cancer [10, 11]. Several studies have been conducted to identify the prognostic significance of PNI in GC, but the results are controversial [12–15]. The question of whether perineural invasion would provide additional prognostic information to the traditional TNM parameters is still debatable.

In this study, we investigated the relationships between PNI and other clinicopathological factors in GC and also assessed the prognostic value of PNI in GC, aiming to provide additional effective prognostic predictors for GC.

2. Patient and Methods

2.1. Patient. The data of 3085 patients (564 Chinese and 2521 Korean) undergoing curative gastrectomy for GC from 2006 to 2010 in two high-volume hospitals in China (West China Hospital, Sichuan University) and Korea (Severance Hospital, Yonsei University Health System) was collected and analyzed, respectively. Eligibility criteria of patients consisted of (1) histologically diagnosed gastric adenocarcinoma, (2) histologically confirmed R0 gastric resection, (3) curative resection with D2 lymphadenectomy, and (4) absence of neoadjuvant chemotherapy or chemoradiation. Patients with distant metastasis including peritoneal dissemination or who had history of other primary tumors or with multiple primary cancers were excluded from the study. Clinical information about nationality, gender, age, tumor location, tumor size, differentiation of tumor, the depth of tumor invasion, lymph node metastasis, TNM staging, lymphatic invasion, vascular invasion, perineural invasion, Borrmann type, and chemotherapy status was obtained and documented. The West China Hospital Research Ethics Committee has approved retrospective analyses of anonymous data from the database. Signed patient informed consent was waived because of the retrospective nature of the analysis.

2.2. Histopathological Evaluation. Tissue samples were obtained from all patients during the surgery and were fixed in 10% formalin, made into paraffin sections, and stained with hematoxylin and eosin in sequence. PNI positivity was identified when carcinoma cells were seen to have infiltrated into the perineurium or neural fascicles. The depth of tumor invasion, lymph node involvement, and distant metastasis, staging, and tumor grade were classified according to the 8th Edition of the AJCC Cancer Staging Manual. Clinical pathologists identified the histologic type of gastric carcinoma in line with the histological classification for gastric carcinoma by the World Health Organization (WHO) [16].

2.3. Treatments. Curative total or subtotal gastrectomy with D2 lymphadenectomy for GC has been performed for all patients according to the Japanese Classification of Gastric Carcinoma [17]. Fluoropyrimidine alone or a fluoropyrimidine/platinum-based regimen was given to the patients who needed chemotherapy treatments after the operation.

2.4. Outcomes. Patients underwent follow-ups conducted by telephone calls, letters, or outpatient visits. Survival status at the last follow-up for Korean patients was also based on data registered in the Korean National Cancer Center. The follow-up information was updated in December 2014 for Chinese patients and March 2014 for Korean patients. The overall follow-up rate was 96.23%. OS was calculated from the date of operation until the date of death or the last follow-up. All terminologies were based on the Japanese Classification of Gastric Carcinoma [18].

2.5. Statistical Analysis. Statistical analyses were performed using SPSS 19.0 (SPSS Inc., Chicago, IL) software. The chi-square test, Fisher exact test, or nonparametric test was used to determine the relationships between the status of PNI and other well-known clinicopathological factors. Survival analysis and curves were presented by the Kaplan-Meier analysis and compared by the log-rank test. Whether PNI would work as a prognostic factor along with other predicting parameters was assessed by the multivariate Cox regression analysis. All P values were two-sided in tests, and P values less than 0.05 were considered to be statistically significant.

3. Results

3.1. Patient Characteristics. From January 2006 to December 2010, a total of 3085 patients were reviewed; then, 116 patients were excluded due to lost to follow-up. The mean durations of follow-up were 55.53 months in Chinese patients and 47.76 months in Korean patients. Data of 2969 patients who had received curative gastrectomy for gastric cancer were retrospectively analyzed. Of the 2969 patients, 1997 were male and 972 were female with the mean age of 57.36 ± 12.02. According to the 8th edition TNM staging system, there were 1018 (34.3%) patients classified as stage I, 723 (24.4%) as stage II, and 1228 (41.4%) as stage III. The majority of the tumors were located in the lower third of the tumor (58.6%), 16.7% in the upper third, and 24.4% in the middle third, and only 0.3% of the tumors involved the whole stomach. Most of the patients (66.3%) had tumors with poor differentiation, 27.3% with moderate differentiation, and 6.3% with well differentiation. 2011 (67.7%) patients underwent distal gastrectomy, 74 (2.5%) patients underwent proximal gastrectomy, and 884 (29.8%) patients underwent total gastrectomy. Approximately half of the included patients (47.9%) accepted chemotherapy after surgery (Table 1).

3.2. Relationship between PNI and Other Clinicopathological Factors. PNI was positive in 35.5% (1055/2969) of patients. The incidence of PNI was significantly higher in Korean patients (P < 0.001) and patients over 60 years old (P = 0.028). Tumors with larger size, poorer differentiation, more advanced clinical stage, and lymphatic invasion were
more easily to be detected as PNI-positive \((P < 0.001)\). Tumor location was also closely related to the incidence of PNI \((P = 0.001)\). On the contrary, no association was found between gender and PNI positivity \((P = 0.055)\) (Table 1).

### 3.3. Prognostic Significance of PNI in Patients Who Underwent Curative Resection

Univariate analysis suggested that PNI had impact on the OS of patients with GC undergoing curative resection (Figure 1). The mean survival time of patients with positive PNI (62.5 months) is much shorter than that of patients without PNI (87.3 months) \((P < 0.001)\). However, the results of multivariate analysis showed that PNI was not an independent prognostic factor for GC patients. By dividing the patients into subgroups according to the staging and reevaluating the prognostic significance of PNI in patients with different TNM stages, we found that the survival curves showed a significant difference between the PNI-positive group and the PNI-negative group only for patients in stage III (Figure 2), while these survival differences could not be observed in stage I and stage II patients \((P = 0.48\) and 0.69 for stage I and stage II, respectively). Rather than stages I and II, furthermore, positive PNI was proved to be an independent prognostic factor for patients in stage III \((P = 0.037,\) hazard ratio: 1.21, 95% confidence interval: 1.01-1.44) in addition to other well-acknowledged clinical-pathological factors including patients’ age \((P < 0.001),\) pT stage \((P < 0.001),\) and pN stage \((P < 0.001)\) in the multivariate analysis, while tumor size, tumor differentiation, vascular invasion, and lymphatic invasion were not significant prognostic factors in multivariate analysis (Table 2).

### 4. Discussion

PNI is the neoplastic invasion of perineurium or neural fascicles, and it has been detected in different types of tumors with the incidence ranging from 6.8% to 75.6% in patients [19]. In many malignancies, such as basal cell carcinoma [20], prostate cancer [21], and pancreatic cancer [22], it was an established risk factor related to the OS of patients. It has also been reported that PNI was associated with 1-year recurrence and poor disease-free survival by Fouquet et al. [23]. The prognostic significance of PNI in GC is still controversial, which was discussed in the current study.

A total of 1055 (35.5%) patients’ specimens showed positive PNI in this study. Factors including nationality, age, tumor location, tumor size, tumor differentiation, stage, lymphatic invasion, and vascular invasion showed close relationships with PNI in tumors, most of whom have been reported in previous studies [13]. Deng et al. [24] found that PNI was significantly associated with N stage, T stage, and tumor vascular invasion in a systematic review, which was in line with the present analysis. They demonstrated that PNI was irrelevant to sex, age, and tumor location, although the last two factors were considered contrarily in our and some other studies [12, 15, 25, 26]. PNI tended to present positive in the upper third, middle third, and entire stomach in our series, which could be explained by the fact that the proportions of \(T_{1-4}\) invasion of tumors located in the upper third

### Table 1: Association between perineural invasion (PNI) and other clinicopathological factors.

|                        | PNI- (%) | PNI+ (%) | \(P\) value |
|------------------------|---------|---------|-------------|
| **Nationality**        |         |         |             |
| Chinese                | 428 (22.4) | 20 (1.9) | <0.001      |
| Korean                 | 1486 (77.6) | 1035 (98.1) |           |
| **Gender**             |         |         | 0.055       |
| Male                   | 1311 (68.5) | 686 (65.0) |           |
| Female                 | 603 (31.5) | 369 (35.0) |           |
| **Age**                |         |         | 0.028       |
| <60                    | 1011 (52.8) | 602 (57.1) |           |
| ≥60                    | 903 (47.2) | 453 (42.9) |           |
| **Tumor location**     |         |         | <0.001      |
| Upper third            | 303 (15.8) | 192 (18.2) |           |
| Middle third           | 412 (21.5) | 313 (29.7) |           |
| Lower third            | 1194 (62.4) | 545 (51.7) |           |
| Whole stomach          | 5 (0.3) | 5 (0.5) |           |
| **Tumor size**         |         |         | <0.001      |
| ≤2 cm                  | 531 (27.7) | 75 (7.1) |           |
| 2.1 - 5 cm             | 953 (49.8) | 521 (49.4) |           |
| 5.1 - 8 cm             | 339 (17.7) | 334 (31.7) |           |
| >8 cm                  | 91 (4.8) | 125 (11.8) |           |
| **Differentiation of tumor** |         |         | <0.001      |
| Well                   | 155 (8.1) | 33 (3.1) |           |
| Moderate               | 576 (30.1) | 236 (22.4) |           |
| Poor                   | 1183 (61.8) | 786 (74.5) |           |
| **pT stage**           |         |         | <0.001      |
| T1                     | 779 (40.7) | 18 (1.7) |           |
| T2                     | 405 (21.2) | 103 (9.8) |           |
| T3                     | 294 (15.4) | 286 (27.1) |           |
| T4a                    | 415 (21.7) | 636 (60.3) |           |
| T4b                    | 21 (1.1) | 12 (1.1) |           |
| **pN stage**           |         |         | <0.001      |
| N0                     | 1084 (56.6) | 237 (22.5) |           |
| N1                     | 298 (15.6) | 172 (16.4) |           |
| N2                     | 257 (13.4) | 229 (21.7) |           |
| N3a                    | 199 (10.4) | 262 (24.8) |           |
| N3b                    | 76 (4.0) | 154 (14.6) |           |
| **Staging**            |         |         | <0.001      |
| Stage I                | 953 (49.8) | 65 (6.1) |           |
| Stage II               | 457 (23.9) | 271 (25.7) |           |
| Stage III              | 504 (26.3) | 719 (68.2) |           |
| **Lymphatic invasion** |         |         | <0.001      |
| Negative               | 1470 (76.8) | 389 (36.9) |           |
| Positive               | 444 (23.2) | 666 (63.1) |           |
| **Vascular invasion**  |         |         | <0.001      |
| Negative               | 1500 (78.4) | 371 (35.2) |           |
| Positive               | 414 (21.6) | 684 (64.8) |           |
| **Chemotherapy**       |         |         | <0.001      |
| No                     | 1277 (66.7) | 269 (25.5) |           |
| Yes                    | 637 (33.3) | 786 (74.5) |           |
higher rate of PNI was found in young (≤40 years) patients compared with older (56-75 years) patients, which corresponded to our analysis. Zhou et al. [26] reported a similar result in their study focused on young Chinese patients. The possible reason might be that the tumors of relatively young patients were often more aggressive and had poorer biological behaviors.

Data from Chinese patients showed that the incidence of PNI (4.5%) was much lower than that in patients from Korea (41.1%) or other previous reports from China [26, 27]. Underreporting by clinical pathologists might be partly responsible for this result. Liebig et al. [28] observed an average of 0.5% of PNI in stage I-IV colorectal cancer in original reports; the detection rate rises to 22% after rereviewing the slides. Peng et al. [29] in their study detected the rate of positivity of PNI in rectal cancer and found that the diagnosis of PNI positivity was missed in 73.8% of patients, compared with the original reports. Fortunately, more attention has been paid to PNI detection for Chinese GC patients currently, and the reported incidence of PNI in pathological examinations has been growing.

Several studies have discussed the prognostic value of PNI in GC, and different opinions were reported in recent years. Tanaka et al. [30] confirmed PNI as a significant prognostic factor in patients with CG, especially for patients with T2 stage. Deng et al. [24] pooled 24 studies in a meta-analysis, which demonstrated that PNI revealed a poor prognosis and affected overall survival and disease-free survival of GC patients who had undergone curative resection. However, significant heterogeneities on the results of overall survival and disease-free survival still exist. Several researchers have also conducted a series of studies that did not recognize PNI as an independent factor predicting outcomes for GC patients [12, 14, 15, 27, 31], and our analysis was in accordance with them. The heterogeneity between studies was probably caused by different ethnicities of patients, types of surgery, degree of lymphadenectomy, staining methods, and interpretation criteria of PNI. We observed that although PNI-positive patients had significantly worse OS than PNI-negative patients in univariate analysis, PNI did not show any additional prognostic value in multivariate Cox regression analysis. It might result from the close relationships between the PNI and advanced T and N stages. Nevertheless, when we divided patients into subgroups and reperformed the Cox regression, PNI was found to play a prognostic role in patients in stage III, along with other factors including age, pT stage, pN stage, and chemotherapy status, indicating that stage III GC patients with positive PNI would have a worse survival outcome than those without. One possible explanation is that PNI was detected much less in TNM I and II stages so that its impact on the OS was veiled during the analysis. Jiang et al. [32] tried to incorporate PNI into the 7th edition TNM staging system. In their study, the difference of survival curves between patients with and without PNI could be found in T4b, N3, and stage III patients, which was consistent with our results. What is notable in the results was that PNI appeared to be a more important prognostic factor than lymphatic and vascular invasion. This finding was somewhat interesting because lymphatic and vascular
invasion could be directly related to lymphatic and hematogeneous metastasis, while the meaning of perineural invasion was relatively biologically ambiguous. However, similar results were obtained in most of the previous studies [12–14, 33, 34]. On the other hand, some researches that reported lymphatic and vascular invasion as independent prognostic factors along with PNI also failed to include other well-acknowledged factors like age, tumor location, and tumor size in the multivariate analysis, which left the results unlikely to be solid [35, 36]. We considered that the possible reason might be because the prognostic value included in the lymphatic and vascular invasion has been partly compensated by other associated factors, such as the N stage and T stage. The limitation of this study mainly consisted of its retrospective design, possible deficiency in pathologic examinations, and a lack of data of disease recurrence, which

| Variables                  | Univariate analysis | Multivariate analysis |
|----------------------------|---------------------|-----------------------|
|                            | HR (95% CI)         | P value               | HR (95% CI)         | P value               |
| Age                        | <0.001              |                       | <0.001              |                       |
| <60                        | 1                   | 1                     | 1                   | 1                     |
| ≥60                        | 1.39 (1.18-1.63)    | 0.047                 | 1.45 (1.23-1.71)    | 0.047                 |
| Tumor location             | 0.008               |                       | 0.047               |                       |
| Upper third                | 1                   |                       | 1                   |                       |
| Middle third               | 0.89 (0.70-1.14)    | 0.87 (0.68-1.11)      | 0.95 (0.77-1.18)    | 0.95 (0.77-1.18)      |
| Lower third                | 0.93 (0.76-1.51)    | 0.95 (0.77-1.18)      | 0.95 (0.77-1.18)    | 0.95 (0.77-1.18)      |
| Whole stomach              | 3.63 (1.60-8.25)    | 2.75 (1.18-6.38)      | 2.75 (1.18-6.38)    | 2.75 (1.18-6.38)      |
| Tumor size                 | <0.001              | 0.18                  | <0.001              | 0.18                  |
| ≤2cm                       | 1                   |                       | 1                   |                       |
| 2.1-5cm                    | 0.96 (0.60-1.53)    | 0.86 (0.53-1.39)      | 0.86 (0.53-1.39)    | 0.86 (0.53-1.39)      |
| 5.1-8cm                    | 1.39 (0.87-2.22)    | 1.01 (0.62-1.64)      | 1.01 (0.62-1.64)    | 1.01 (0.62-1.64)      |
| >8cm                       | 1.80 (1.11-2.94)    | 1.10 (0.66-1.84)      | 1.10 (0.66-1.84)    | 1.10 (0.66-1.84)      |
| Differentiation of tumor   | 0.03                | 0.468                 | 0.468               | 0.468                 |
| Well                       | 1                   |                       | 1                   |                       |
| Moderate                   | 1.35 (0.66-2.75)    | 1.18 (0.58-2.43)      | 1.18 (0.58-2.43)    | 1.18 (0.58-2.43)      |
| Poor                       | 1.70 (0.85-3.43)    | 1.32 (0.65-2.67)      | 1.32 (0.65-2.67)    | 1.32 (0.65-2.67)      |
| pT stage                   | <0.001              | <0.001                | <0.001              | <0.001                |
| T1                         | 1                   |                       | 1                   |                       |
| T2                         | 0.68 (0.21-2.23)    | 0.86 (0.25-2.94)      | 0.86 (0.25-2.94)    | 0.86 (0.25-2.94)      |
| T3                         | 0.45 (0.14-1.43)    | 0.74 (0.22-2.45)      | 0.74 (0.22-2.45)    | 0.74 (0.22-2.45)      |
| T4a                        | 0.76 (0.25-2.38)    | 1.27 (0.39-4.15)      | 1.27 (0.39-4.15)    | 1.27 (0.39-4.15)      |
| T4b                        | 2.08 (0.63-6.85)    | 3.43 (0.99-11.91)     | 3.43 (0.99-11.91)   | 3.43 (0.99-11.91)     |
| pN stage                   | <0.001              | <0.001                | <0.001              | <0.001                |
| N0                         | 1                   |                       | 1                   |                       |
| N1                         | 0.63 (0.87-4.60)    | 1.25 (0.17-9.51)      | 1.25 (0.17-9.51)    | 1.25 (0.17-9.51)      |
| N2                         | 0.93 (1.30-6.65)    | 2.21 (0.30-16.54)     | 2.21 (0.30-16.54)   | 2.21 (0.30-16.54)     |
| N3a                        | 1.58 (0.22-11.32)   | 3.59 (0.48-26.78)     | 3.59 (0.48-26.78)   | 3.59 (0.48-26.78)     |
| N3b                        | 2.94 (0.41-21.00)   | 6.60 (0.88-49.31)     | 6.60 (0.88-49.31)   | 6.60 (0.88-49.31)     |
| Vascular invasion          | 1.16 (0.98-1.37)    | 0.08                  | 0.08                |                       |
| Lymphatic invasion         | 1.17 (0.99-1.38)    | 0.07                  | 0.07                |                       |
| Chemotherapy               | 0.001               |                       | <0.001              |                       |
| No                         | 1                   |                       | 1                   |                       |
| Yes                        | 0.73 (0.61-0.88)    | 0.67 (0.55-0.81)      | 0.67 (0.55-0.81)    | 0.67 (0.55-0.81)      |
| Perineural invasion        | 0.032               | 0.037                 | 0.037               |                       |
| Negative                   | 1                   |                       | 1                   |                       |
| Positive                   | 1.20 (1.02-1.42)    | 1.21 (1.01-1.44)      | 1.21 (1.01-1.44)    | 1.21 (1.01-1.44)      |
| Country                    | 0.38                | 1.19                  | 1.19                |                       |
| Korea                      | 1                   |                       | 1                   |                       |
| China                      | 1.09 (0.90-1.33)    |                       | 1.09 (0.90-1.33)    |                       |
prevented us from further exploring the impact of PNI on disease-free survival of GC patients. Secondly, the regimens and courses of chemotherapy were factors that could influence the prognosis, which were not analyzed. Another limitation was that about >98% of perineural invasion was from the Korean hospital as we have addressed above, which might bias the results. Therefore, we included the institutions as a confounding variable to perform the Cox regression analysis and found that the institutions were not an independent prognostic factor and had no impact on the OS of patients. To our limited knowledge, however, this is the first international multicenter study considering the impact of PNI on GC, and the large sample size could guarantee the relative authenticity of our study.

5. Conclusion

PNI occurs frequently in patients with gastric cancer, and the incidence of PNI increases with the staging of tumors. PNI is not an independent prognostic factor for overall GC patients, but the presence of PNI can provide additional information in predicting the survival outcome for those with stage III tumors.

Data Availability

The data that support the findings of this study are available from the corresponding authors upon reasonable request.

Additional Points

Synopsis. This study found that the presence of PNI was not an independent prognostic factor for gastric cancer, except for patients in stage III. The importance of this finding is to provide additional information in predicting the survival outcome for stage III gastric cancer patients.

Conflicts of Interest

Dr. Woo Jin Hyung is a consultant for Ethicon and Verb Surgical and has Grants from Medtronic & GC Pharma and stock in Hutom. Drs. Kun Yang, Yu-Qing Dan, Yoon Young Choi, Zong-Guang Zhou, Jian-Kun Hu, and Sung Hoon Noh have no conflicts of interest or financial ties to disclose.

Authors’ Contributions

Study conception and design were handled by Yang, Hu, and Noh. Acquisition of data was taken care of by Yang, Dan, Choi, Zhou, and Hyung. Analysis and interpretation of data were conducted by Yang, Dan, Hu, and Noh. Drafting of the manuscript was worked on by Yang and Dan. Critical revision was managed by Yang, Hu, and Noh.

Acknowledgments

The study was supported by domestic support from the (1) National Natural Science Foundation of China (No. 81772547), (2) Fundamental Research Funds for the Central Universities (No. 2017SCU04A18), (3) Young scientific and academic leaders training program of Sichuan University (No. 0082604151001/035), (4) Foundation of Science & Technology Department of Sichuan Province (No. 2019YFS0256), and (5) 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (No. ZY2017304).

References

[1] J. Ferlay, I. Soerjomataram, R. Dikshit et al., “Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012,” International Journal of Cancer, vol. 136, no. 5, pp. E359–E386, 2015.

[2] C. Allemani, H. K. Weir, H. Carreira et al., “Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2),” The Lancet, vol. 385, no. 9972, pp. 977–1010, 2015.

[3] Z. Sun, Z. N. Wang, Z. Zhu et al., “Evaluation of the seventh edition of American Joint Committee on Cancer TNM staging system for gastric cancer: results from a Chinese monoinstitutional study,” Annals of Surgical Oncology, vol. 19, no. 6, pp. 1918–1927, 2012.

[4] Z. Zhang, J. Y. Huang, P. L. Wang, W. B. Hou, S. C. Yin, and H. M. Xu, “Should all stage N3b patients with advanced gastric cancer be considered equivalent? A 30-year single center study,” Journal of Gastrointestinal Surgery, vol. 23, no. 9, pp. 1742–1747, 2019.

[5] S. Kikuchi, N. Futawatari, S. Sakuramoto et al., “Comparison of staging between the old (6th edition) and new (7th edition) TNM classifications in advanced gastric cancer,” Anticancer Research, vol. 31, no. 6, pp. 2361–2365, 2011.

[6] S. G. Kim, H. S. Seo, H. H. Lee, K. Y. Song, and C. H. Park, “Comparison of the differences in survival rates between the 7th and 8th editions of the AJCC TNM staging system for gastric adenocarcinoma: a single-institution study of 5,507 patients in Korea,” Journal of Gastric Cancer, vol. 17, no. 3, pp. 212–219, 2017.

[7] O. Algan, W. H. Pinover, A. L. Hanlon, T. I. al-Saleem, and G. E. Hanks, “Is there a subset of patients with PSA? 20 ng/ml who do well after conformal beam radiotherapy?,” Radiation Oncology Investigations, vol. 7, no. 2, pp. 106–110, 1999.

[8] P. Bassi, G. D. Ferrante, N. Piazza et al., “Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort,” The Journal of Urology, vol. 161, no. 5, pp. 1494–1497, 1999.

[9] S. Kondo, T. Takada, M. Miyazaki et al., “Guidelines for the management of biliary tract and ampullary carcinomas: surgical treatment,” Journal of Hepato-Biliary-Pancreatic Surgery, vol. 15, no. 1, pp. 41–54, 2008.

[10] H. Ozaki, T. Hiraoka, R. Mizumoto et al., “The prognostic significance of lymph node metastasis and intrapancreatic perineural invasion in pancreatic cancer after curative resection,” Surgery Today, vol. 29, no. 1, pp. 16–22, 1999.

[11] T. Takahashi, H. Ishikura, T. Motohara, S. Okushiba, M. Dohke, and H. Katoh, “Perineural invasion by ductal adenocarcinoma of the pancreas,” Journal of Surgical Oncology, vol. 65, no. 3, pp. 164–170, 1997.

[12] N. Duraker, S. Sişman, and G. Can, “The significance of perineural invasion as a prognostic factor in patients with gastric carcinoma,” Surgery Today, vol. 33, no. 2, pp. 95–100, 2003.
A. Bilici, M. Seker, B. B. Ustaalioglu et al., "Prognostic significance of perineural invasion in patients with gastric cancer who underwent curative resection," *Annals of Surgical Oncology*, vol. 17, no. 8, pp. 2037–2044, 2010.

P. Aurello, G. Berardi, S. M. Tierno et al., "Influence of perineural invasion in predicting overall survival and disease-free survival in patients with locally advanced gastric cancer," *American Journal of Surgery*, vol. 213, no. 4, pp. 748–753, 2017.

L. de Franco, D. Marrelli, C. Voglino et al., "Japanese Gastric Cancer Association, "Japanese classification of gastric carcinoma -2nd English edition," *Gastric Cancer*, vol. 1, no. 1, pp. 10–24, 1998.

Japanese Gastric Cancer Association, "Japanese classification of gastric carcinoma -2nd English edition," *Gastric Cancer*, vol. 1, no. 1, pp. 10–24, 1998.

C. Liebig, G. Ayala, J. A. Wilks, D. H. Berger, and D. Albo, "Perineural invasion in cancer: a review of the literature," *Cancer*, vol. 115, no. 15, pp. 3379–3391, 2009.

H. W. Walling, S. W. Fosko, P. A. Geraminejad, D. C. Whittaker, and C. J. Arpey, "Aggressive basal cell carcinoma: presentation, pathogenesis, and management," *Cancer Metastasis Reviews*, vol. 23, no. 3/4, pp. 389–402, 2004.

P. Harnden, M. D. Shelley, H. Clements et al., "The prognostic significance of perineural invasion in prostatic cancer biopsies: a systematic review," *Cancer*, vol. 109, no. 1, pp. 13–24, 2007.

I. Hirai, W. Kimura, K. Ozawa et al., "Perineural invasion in pancreatic cancer," *Pancreas*, vol. 24, no. 1, pp. 15–25, 2002.

T. Fouquet, A. Germain, L. Brunaud, L. Bresler, and A. Ayav, "Is perineural invasion more accurate than other factors to predict early recurrence after pancreatoduodenectomy for pancreatic head adenocarcinoma?" *World Journal of Surgery*, vol. 38, no. 8, pp. 2132–2137, 2014.

J. Deng, Q. You, Y. Gao et al., "Prognostic value of perineural invasion in gastric cancer: a systematic review and meta-analysis," *PLoS One*, vol. 9, no. 2, article e88907, 2014.

F. J. Hsieh, Y. C. Wang, J. T. Hsu et al., "Clinicopathological features and prognostic factors of gastric cancer patients aged 40 years or younger," *Journal of Surgical Oncology*, vol. 105, no. 3, pp. 304–309, 2012.

F. Zhou, J. Shi, C. Fang, X. Zou, and Q. Huang, "Gastric carcinomas in young (younger than 40 years) Chinese patients: clinicopathology, family history, and postresection survival," *Medicine*, vol. 95, no. 9, article e2873, 2016.

Z. H. Zhou, G. F. Xu, W. J. Zhang, H. B. Zhao, and Y. Y. Wu, "Reevaluating significance of perineural invasion in gastric cancer based on double immunohistochemical staining," *Archives of Pathology & Laboratory Medicine*, vol. 138, no. 2, pp. 229–234, 2014.

C. Liebig, G. Ayala, J. Wilks et al., "Perineural invasion is an independent predictor of outcome in colorectal cancer," *Journal of Clinical Oncology*, vol. 27, no. 31, pp. 5131–5137, 2009.

J. Peng, W. Sheng, D. Huang et al., "Perineural invasion in pT3N0 rectal cancer: the incidence and its prognostic effect," *Cancer*, vol. 117, no. 7, pp. 1415–1421, 2011.